Develops antibody and fusion-protein drug candidates for people with severe autoimmune diseases.
Sources
10-K for FY2025, filed Mar 9, 2026
We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe…View ↗
Our second clinical-stage candidate, DNTH212, is a first and potentially best-in-class, bifunctional fusion protein that targets…View ↗
How Do They Make Money?
The company licenses antibody rights to partners for research, development and commercialization in Greater China. License terms include upfront payments, cost reimbursements and development milestones, plus royalties on licensed products’ net sales.
Sources
10-K for FY2025, filed Mar 9, 2026
On June 10, 2022, in connection with Zenas’s exercise of the option, we entered into a license agreement with Zenas (the “Zenas License…View ↗
As consideration for the license, which replaced the consideration of the Zenas License Agreement with respect to the first antibody…View ↗
The company licenses drug candidates to other companies: Tenacia holds the Greater China license for claseprubart, and Leads holds an exclusive license for DNTH212.
Sources
10-K for FY2025, filed Mar 9, 2026
As consideration for the license, which replaced the consideration of the Zenas License Agreement with respect to the first antibody…View ↗
On October 16, 2025, we entered into an exclusive license agreement with Nanjing Leads Biolabs Co., Ltd. (“Leads”) for DNTH212, a first and…View ↗
From transplant to autoimmune therapies
The older report centered on candidates for stem-cell conditioning and mobilization; the latest report centers on drug candidates for severe autoimmune diseases.
Sources
10-K for FY2022, filed Mar 23, 2023
Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation.View ↗
Our product candidates have been designed to improve the patient experience when preparing for stem cell transplant or gene therapy. Our…View ↗
10-K for FY2025, filed Mar 9, 2026
We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe…View ↗
Our second clinical-stage candidate, DNTH212, is a first and potentially best-in-class, bifunctional fusion protein that targets…View ↗
Who Do They Compete With?
Competes with AstraZeneca, argenx, UCB, Johnson and Johnson, Amgen, Pfizer, CSL Behring, Grifols Therapeutics, Sanofi, and Takeda
Sources
10-K for FY2025, filed Mar 9, 2026
There is significant competition in gMG. AstraZeneca’s Soliris® and Ultomiris®, both I.V. C5 inhibitors, argenx’s Vyvgart® (efgartigimod)…View ↗